Relay Therapeutics rises on positive data for zovegalisib

Shares of US precision medicines company Relay Therapeutics (Nasdaq: RLAY) were up 11.3% at $12.10 in pre-market activity today, after it announced highly encouraging initial clinical data from the Phase ReInspire trial of zovegalisib in vascular anomalies signaling the advantage of PI3Kα mutant-selective inhibition.

Vascular anomalies are a group of rare disorders characterized by abnormal development of blood vessels, lymphatic vessels and surrounding tissues. As of the April 15, 2026 data cut-off date, in the Part 1 dose randomization portion of the study for adults and adolescents ages 12 and up, 60% of patients achieved a volumetric response at the earliest time point (12 weeks) and nearly all patients experienced symptomatic improvement at 12 weeks while maintaining a safety and tolerability profile showing the potential for chronic use.